Prognosis

AstraZeneca Vaccine Data Appear Less Competitive, Analysts Say

Data fail to meet the bar set by Pfizer and Moderna: Bernstein
New York shares erase initial pop to fall the most since March

AstraZeneca Covid Vaccine Shows Promise in Early Human Testing

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Bailey Lipschultz

July 20, 2020 at 5:42 PM UTC

This article is for subscribers only.

AstraZeneca Plc fell from a record high in New York trading after data for the company’s Covid-19 vaccine candidate, though promising, fueled concerns about whether it can match competitors.

Bernstein analysts led by Ronny Gal said the vaccine, developed in partnership with the University of Oxford, showed early positive data, but the benefits didn’t appear to match the bar set by programs from Pfizer Inc. and BioNtech SE, as well as Moderna Inc.